GLOD4

Across TCGA pan-cancer cohorts, GLOD4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLOD4 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLOD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLOD4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where GLOD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.750	0.236	<.001	52	view →
PDAC	DFS	Tertile	All	0.509	0.275	<.001	48	view →
UCEC	DFS	Quartile	All	0.954	0.711	.020	10	view →
LUAD	DFS	Quartile	All	0.968	0.649	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GLOD4–CCRCC (DFS)

Open the CCRCC breakdown →